A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose Escalation, Single Center Bridging Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects
Latest Information Update: 04 Jul 2022
At a glance
- Drugs ASC 42 (Primary)
- Indications Cholangitis; Hepatitis B; Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Ascletis
- 28 Jun 2022 Status changed from active, no longer recruiting to completed.
- 18 Oct 2021 Planned End Date changed from 30 Sep 2021 to 20 Feb 2022.
- 19 Aug 2021 Status changed from recruiting to active, no longer recruiting.